Metformina Stada (Metformin Hydrochloride)

Metformina Stada (metformin) is used primarily in the management of disorders related to impaired glucose metabolism.

• Type 2 diabetes mellitus: improves glycemic control by reducing fasting plasma glucose and HbA1c.
• Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes by enhancing insulin sensitivity.
• Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity and androgen levels.

• Metformin hydrochloride acts as a biguanide that inhibits mitochondrial respiratory-chain complex I, leading to reduced hepatic gluconeogenesis. It also increases peripheral glucose uptake by activating AMP‑activated protein kinase (AMPK), which enhances insulin sensitivity in muscle and adipose tissue, thereby lowering circulating glucose levels.

Metformina Stada may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: frequent loose stools, especially at treatment initiation.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: life‑threatening metabolic acidosis, especially in renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic failure: rare but possible liver dysfunction.
• Hypoglycemia: uncommon when used alone but may occur with other glucose‑lowering agents.
• Acute pancreatitis: very rare inflammatory condition of the pancreas.

Before prescribing Metformina Stada, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function: assess creatinine clearance and avoid use in severe renal impairment.
• Hepatic function: avoid in patients with significant liver disease.
• Cardiovascular status: monitor for signs of heart failure.
• Concomitant alcohol: limit intake to reduce risk of lactic acidosis.
• Pregnancy and lactation: evaluate risk‑benefit; use only if clearly needed.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Metformina Stada can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Contrast media (iodinated): may precipitate lactic acidosis.
• Cimetidine: can increase metformin plasma concentrations.
• Alcohol abuse: heightens risk of metabolic acidosis.
• Acute heart failure: exacerbates risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• Corticosteroids: may raise blood glucose, requiring dose adjustment.
• Thyroid hormones: may alter glucose metabolism.
• Oral contraceptives: may increase risk of vitamin B12 deficiency.